NGM Biopharmaceuticals

$28.43
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.17 (+4.29%) As of 6:19 PM UTC today

Why Robinhood?

You can buy or sell NGM and other stocks, options, and ETFs commission-free!

About NGM

NGM Biopharmaceuticals, Inc. Common Stock, also called NGM Biopharmaceuticals, is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for cardio-metabolic, liver, oncologic, and ophthalmic diseases. Its portfolio include aldafermin (NGM282), NGM313, NGM120, NGM217, NGM621, and NGM395. The company was founded by Jin-Long Chen in 2008 and is headquartered in South San Francisco, CA. The listed name for NGM is NGM Biopharmaceuticals, Inc. Common Stock.

CEO
David J. Woodhouse
Employees
186
Headquarters
South San Francisco, California
Founded
2008
Market Cap
2.07B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
275.97K
High Today
$28.54
Low Today
$26.49
Open Price
$27.12
Volume
153.40K
52 Week High
$32.05
52 Week Low
$9.25

NGM Earnings

-$0.43
-$0.29
-$0.14
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 17, After Hours

You May Also Like

CALM
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure